Neurolixis CEO, Adrian Newman-Tancredi, PhD, DSc, was interviewed by the regional business accelerator of Castres-Mazamet, in southern France, which has been supporting the company since 2014. Adrian outlined his background in neuroscience research, starting with doctoral research in the UK, before moving to industrial pharmaceutical research at Servier, Pierre Fabre and now Neurolixis. A recent highlight is the launch of a clinical trial on NLX-112 for treatment of dyskinesia in Parkinson's disease, the fruit of a decade of work on movement disorders (see previous press release). 
See full interview (in French) here.

 

 

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: